Philippe GUÉDAT, PhD
Founder, President, Chief Executive Officer
Dr Philippe Guédat has over 20 years of experience in drug discovery in the industry. Philippe held different positions of responsibility in different “business units”. He was the Director of Chemistry at Hybrigenics and the head of the drug discovery department at Vivalis (now Valneva).
His expertise ranges from the discovery of chemical molecules with the implementation of high-throughput screening platforms to clinical development of drug candidates. Medicinal chemist by training, he optimized many chemical series in a variety of therapeutic areas and filed more than 20 patent families. He has been a consultant for several biopharmaceutical companies and “reviewer” for scientific journals. He is the author of 18 scientific publications.
Philippe has a Master’s degree in medicinal chemistry and pharmacology, a Master’s degree of supramolecular organic chemistry and a PhD in medicinal chemistry and pharmacology from the University Louis Pasteur (Strasbourg). Philippe worked at the University of Cambridge (UK), SmithKline Beecham (UK), Merck-Serono, Hybrigenics and Vivalis (now Valneva). In 2013, he founded InFlectis BioScience where he is acting as President and Chief Executive Officer since inception.
Pierre MINIOU, PhD, MBA
Founder & Chief Operating Officer
Dr Pierre Miniou has over 15 years of international experience in business development and licensing in the biopharmaceutical industry with the signing of many partnering and license agreements. He has experience of senior management having been the head of the patent department of Pierre Fabre Laboratories, a member of the Executive Committee of Vivalis (now Valneva) and Director of Vivalis Toyama (Japan).
Pierre holds a Master’s degree and Engineering degree in Biotechnology from the School of Biotechnology of Strasbourg and a PhD in Molecular and Cellular Biology from the Louis Pasteur University of Strasbourg. He is also graduated from the CEIPI (Centre for International Studies of Industrial Property) in Strasbourg and holds a MBA (Audencia, Nantes).
He worked as a researcher at Transgene (Strasbourg), the Wistar Institute (Philadelphia, PA), the Necker Hospital (Paris) and the IGBMC (Strasbourg). He then left the laboratory activities to join the law firm Cabinet Regimbeau (Paris) prior to join Pierre Fabre Laboratories and in 2003 he move to Vivalis (today Valneva) as Director of Business Development and Director of Intellectual Property. In 2013, he founded InFlectis BioScience where he is acting as Chief Operating Officer.
Anne VISBECQ, MD
Chief Medical Officer
Anne Visbecq is a Medical Doctor with over 20 years of experience in the pharmaceutical industry. She obtained her medical degree with thesis award (University of Nantes), and then completed her training with university degrees in clinical research and oncopharmacology. She also has Master’s degrees in pharmacology, biostatistics and health management.
Anne joined the pharmaceutical industry in 1997 and worked as medical advisor in infectious diseases and endocrinology. She then became the head of medical group in an international company (Pharmacia & Upjohn), managing 6 therapeutic areas. She also gained marketing and communication experience to broader her knowledge and better understand the global functioning of pharmaceutical industry and the interactions between departments (Pfizer). Her last position was medical director at Keocyt a company specialized in oncology and neurology. She had to deal with clinical trials, relationships with opinion leaders, business development and procedures of Marketing Authorization. In her professional pathway, she has been employed in very small companies as well as big pharma.
Meanwhile, she has been consultant in medical affairs for years. Thanks to this extensive and diversified experience, her expertise ranges from drug development to launch.
Philippe JAFFRÉ, MBA
Chief Financial Officer
Philippe Jaffré has over 20 years of experience in the finance arena. He has held different executive positions at national, European and global level in biotechnology, consumer health and financial services working for early-stage startups as well as companies “on the bubble” or more established international organizations. His experience covers fundraising, investor relations, M&A, financial strategy, FP&A/controlling, accounting & reporting, taxation, corporate legal, human resources, and administration. Besides, he has held board positions at Dana Capital and Xenothera, which he co-founded.
Philippe Jaffré is a graduate from the SKEMA Nice Business School and has a MBA from the Pennsylvania State University. He began his career with the Dana group, a Fortune 250 company, in car component manufacturing and financial services. After developing the division’s financial strategy and organization in Europe as Finance Director EMEA, Blood Testing Division at Chiron Corp. in the years 2001/2002, he joined the Medical Nutrition Division of Novartis. Initially, he served in Munich as Head of Business Planning & Analysis for Germany and Austria, and then at EMEA level at Headquarters in Geneva, Switzerland. More recently, he moved on to startups in the biotechnology sector where he worked as CFO for TcLand Expression over the period 2007/2012 and InFlectis BioScience since the end of the year 2014.
Béatrice LEJEUNE, Ind Pharm
Chief Regulatory Officer
Béatrice Lejeune graduated from the University of Louvain Pharmacy School (Belgium). After working as a Research Associate in Pharmacogenomics at the University of Florida, she went back to Belgium where she started working in the pharmaceutical industry. After three years in the veterinary field, she joined an international pharmaceutical group specialized in low dose immunotherapy were she stayed for 17 years. While occupying pharmaceutical key positions such as head of QC, then QA, she completed her pharmaceutical education as an Industrial Pharmacist, and became QP.
She moved to France in 2010, and developped cross functional projects skills while leading preclinical and clinical projects, managing the recombinant human proteins production unit based in Spain, and the regulatory affairs department for the group, occupuying Head of RA position during which 5 marketing authorisations were granted.
Her experience allows her to have a broad vision of the course of a drug, from the active substance to the patient intake.